scientific Sessions

Liquid biopsy represents a transformative approach in cancer diagnostics, utilizing minimally invasive blood samples to detect tumor-derived biomarkers like circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). Unlike traditional biopsy methods, which require tissue samples, liquid biopsy offers a less invasive option for cancer detection. At the Cancer Research and Development Conference 2025, experts will explore how this cutting-edge technique revolutionizes the field by enabling early cancer detection, monitoring treatment response in real time, and identifying genetic mutations for more personalized therapies. As advancements in liquid biopsy continue to improve its accuracy and reliability, this technology is becoming an indispensable tool in cancer research, offering a glimpse into the future of precision medicine and improving patient outcomes through timely interventions.